Anthropic’s AI discovers a new mechanism for genetic editing

There is a fundamental contradiction that has long run through the narrative of Silicon Valley: the tendency to oscillate between the apocalyptic tone of existential risk and the messianic tone of technological salvation.

Just a few days ago, the public debate was dominated by catastrophic scenarios following statements by researchers at Anthropic – with internal warnings that AI could lead to human extinction within the decade – which were followed by official statements from CEO Dario Amodei, who called for a controlled slowdown in the sector, and public support from figures such as Elon Musk. Yet, with disarming nonchalance, the very same premises are now being turned on their head to foreshadow the imminent eradication of almost every human disease. Amidst this swing between catastrophism and biological utopia lies the latest announcement from Anthropic, the company developing the Claude model.

The scientific fact, stripped of all propaganda, is undoubtedly intriguing. Set loose on a vast genomic database with just a single guiding prompt, Claude co-ordinated around 950 agents in parallel for 21 consecutive hours. It sifted through hundreds of thousands of DNA sequences, narrowed down the field with the tenacity of a bloodhound, and finally identified something that had eluded human biologists: an enzymatic system based on a reverse transcriptase associated with a series of uniformly spaced repetitive sequences. The researchers have named it ART (array-associated reverse transcriptases). A molecular arrangement that closely resembles the structure of CRISPR, the bacterial immune system that has revolutionised gene editing over the last decade.

In biological terms, the discovery is genuine. Even Feng Zhang, a professor at MIT and one of the pioneers of molecular scissors, acknowledged this, describing the result as “genuinely exciting”. And Amodei himself, with self-deprecating humour measured down to the millimetre, commented that the discovery of this molecular machine in bacteriophages represents “a piece of work I would have been proud of as a PhD student”. The machine read the literature, sifted through the data, spotted the anomaly and even suggested the bench-top experiments that real-life scientists then carried out in the laboratory to confirm that the array is indeed expressed in short RNA sequences.

And yet, reading the pre-print released by Anthropic with a touch of scepticism, it is difficult to separate the scientific revelation from the public relations moment. The publication comes hot on the heels of yet another round of controversy and reports on the ‘existential risks’ associated with next-generation models. Anthropic’s move has a distinctly defensive flavour: what better way to allay fears of a destructive AI than to show the world that your model is laying the foundations for the medicine of the future?

What is needed, in fact, is a touch of secular clarity. As the authors of the paper themselves admit with a modicum of modesty, the precise biological function of ART remains unknown. We do not know whether it really functions as an editing tool, nor whether it will ever have any concrete biotechnological utility or be applicable to humans. To turn the identification of a genomic pattern into the implicit promise of a universal cure is to confuse the first stage of a Grand Prix with the finish line. Biomedical progress is an gruelling marathon stretching from basic biology to clinical trials, via the complex process of delivering medicines to patients; a journey where failures in the test tube number in the thousands.

This in no way detracts from the value of the method. Seeing an agent-based architecture process 210 million tokens to carry out, in less than a day, a sifting task that would have taken a team of researchers months is confirmation that the trajectory of AI applied to the life sciences is not merely a marketing ploy. Amodei often refers to his essay "Machines of Loving Grace" and the exponential trajectory of models which, having stumbled over secondary school equations in 2023, have now reached the point where they are tackling open problems in mathematics. Biology could follow a similar trajectory.

But in the meantime, amidst press releases and pre-prints – whether the brainchild of the model itself or the PR department’s strategy – we would do well to keep a cool head. Artificial intelligence will not wipe us out by 2030, but nor will it cure all the world’s diseases within the same timeframe. In between lies real science: made up of brilliant algorithmic insights, human laboratories tasked with verifying the data and, above all, a public that must learn to distinguish between the advancement of knowledge and a sophisticated public relations campaign.